Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.20) by $0.19. The business had revenue of $6.30 million for the quarter, compared to the consensus estimate of $5.53 million. Keryx Biopharmaceuticals had a negative net margin of 590.50% and a negative return on equity of 172.04%. The business’s revenue was up 50.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.29) EPS.

Keryx Biopharmaceuticals (NASDAQ:KERX) opened at 5.62 on Friday. The stock’s 50 day moving average price is $4.95 and its 200 day moving average price is $5.43. Keryx Biopharmaceuticals has a 1-year low of $2.80 and a 1-year high of $7.80. The stock’s market capitalization is $595.13 million.

Earnings History for Keryx Biopharmaceuticals (NASDAQ:KERX)

Several hedge funds have recently added to or reduced their stakes in the company. Rice Hall James & Associates LLC boosted its stake in Keryx Biopharmaceuticals by 1.3% in the second quarter. Rice Hall James & Associates LLC now owns 912,830 shares of the biopharmaceutical company’s stock valued at $6,043,000 after buying an additional 11,767 shares in the last quarter. LMR Partners LLP acquired a new stake in Keryx Biopharmaceuticals during the second quarter valued at about $125,000. Cambridge Investment Research Advisors Inc. boosted its stake in Keryx Biopharmaceuticals by 38.2% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 18,100 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 5,000 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in Keryx Biopharmaceuticals by 99.0% in the second quarter. Janney Montgomery Scott LLC now owns 84,209 shares of the biopharmaceutical company’s stock valued at $490,000 after buying an additional 41,894 shares in the last quarter. Finally, Shufro Rose & Co. LLC boosted its stake in Keryx Biopharmaceuticals by 41.6% in the second quarter. Shufro Rose & Co. LLC now owns 78,000 shares of the biopharmaceutical company’s stock valued at $516,000 after buying an additional 22,900 shares in the last quarter. Hedge funds and other institutional investors own 61.49% of the company’s stock.

A number of brokerages have recently issued reports on KERX. Vetr downgraded Keryx Biopharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.11 price target for the company. in a research report on Thursday. Maxim Group upgraded Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research report on Wednesday. Zacks Investment Research upgraded Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 1st. FBR & Co restated a “market perform” rating and issued a $7.00 target price on shares of Keryx Biopharmaceuticals in a research report on Tuesday, October 18th. Finally, JMP Securities restated an “outperform” rating on shares of Keryx Biopharmaceuticals in a research report on Thursday, September 8th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $8.28.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.

5 Day Chart for NASDAQ:KERX

Receive News & Stock Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related stocks with our FREE daily email newsletter.